Questionnaire-revised - Assofertilizzanti

thirdsafflowerBiotechnology

Dec 1, 2012 (4 years and 6 months ago)

249 views






GENERAL INFORMATION

Company name

(and related Group)
:

NEWRON PHARMACEUTICALS
S.p.A.

Address:

V
ia L. Ariosto, 21

City/code:

20091 Bresso (Milano)

Country:

Italy

Website:

www.newron.com

Contact persons’ E
-
mail: emanuela.germi@newron.com





GENERAL
BUSINESS INFORMATION

Business model (R&D, production, marketing and sales, services...)
:


R&D







Location of biotechnology lab/plant(s):


Bresso (Milano) via L. Ariosto 21



Staff (in biotech
-
related activities):

~ 40


Collaboration/join
t v
enture agreements in biotech

with:



Newron and Dynogen signed in October 2004 an exclusive, worldwide licence
agreement under which the Boston company obtained rights to certain Newron
compounds in order to explore their clinical potential for genitourinar
y and
gastrointestinal disorders.

Newron has established key scientific collaborations with universities and research
institutions worldwide.





INTEREST OR ACTIVITY IN BIOTECHNOLOGY

Interest/activity in biotechnology started in (year):

1999


Applicati
on fields:

Central Nervous System (CNS)


Parkinson’s Disease, Restless Leg Syndrome, Neuropathic pain





Technologies:


Newron now has two compounds in clinical trials for three indications: safinamide in
Phase III for the treatment of Parkinson’s diseas
e and in Phase II for the treatment of
Restless Legs Syndrome; and Ralfinamide, a novel compound for the treatment of
neuropathic pain in Phase II. Additional projects are in the preclinical phase.


DESCRIPTION OF PROJECTS AT R&D OR PILOT SCALE STAGE







DESCRIPTION OF PRODUCTS & SERVICES


Newron’s lead product, safinamide, is currently in Phase III trials for the treatment
of Parkinson’s disease and in Phase II for Restless Leg Syndrome. Safinamide is
a unique molecule with multiple mechanisms of action
and a very high therapeutic
index.


Ralfinamide: a novel compound of the alpha
-
aminoamide family with potent
sodium channel blocker properties, for the treatment of neuropathic pain.


ADDITIONAL INFORMATION


To date Newron has raised more th
an Euro 62 million from leading life sciences


venture capital funds